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ABSTRACT Recent studies suggest a close interaction
betweenepidermalgrowthfactor (EGF)andTLRsignaling
in the modulation of intestinal epithelial cell (IEC) pro-
liferation; however, how these signaling pathways adjust
IEC proliferation is poorly understood. We utilized
a model of total parenteral nutrition (TPN), or enteral
nutrient deprivation, to study this interaction as TPN
results in mucosal atrophy due to decreased IEC pro-
liferation and increased apoptosis.We identiﬁed the novel
ﬁnding of decreased mucosal atrophy in TLR4 knockout
(TLR4KO) mice receiving TPN. We hypothesized that
EGF signaling is preserved in TLR4KO-TPN mice and
prevents mucosal atrophy. C57Bl/6 and strain-matched
TLR4KO mice were provided either enteral feeding or
TPN. IEC proliferation and apoptosis were measured.
Cytokine and growth factor abundances were detected in
both groups. To examine interdependence of these path-
ways, ErbB1 pharmacologic blockade was used. The
marked decline in IEC proliferation with TPN was nearly
prevented in TLR4KO mice, and intestinal length was
partially preserved. EGF was signiﬁcantly increased, and
TNF-a decreased in TLR4KO-TPN versus wild-type (WT)-
TPN mice. Apoptotic positive crypt cells were 15-fold
higher in WT-TPN versus TLR4KO-TPN mice. Bcl-2 was
signiﬁcantly increased in TLR4KO-TPN mice, while Bax
decreased 10-fold. ErbB1 blockade prevented this other-
wise protective effect in TLR4KO-sTPN mice. TLR4
blockade signiﬁcantly prevented TPN-associated atrophy
by preserving proliferation and preventing apoptosis. This
is drivenbya reduction inTNF-a abundanceand increased
EGF. Potential manipulation of this regulatory pathway
may have signiﬁcant clinical potential to prevent TPN-
associated atrophy.—Freeman, J. J., Feng, Y., Demehri,
F. R., Dempsey, P. J., Teitelbaum, D. H. TPN-associated
intestinal epithelial cell atrophy is modulated by TLR4/
EGF signaling pathways. FASEB J. 29, 2943–2958 (2015).
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TOTAL PARENTERALNUTRITION(TPN) isutilized fornutritional
support for over 375,000 U.S. patients each year who are
unable to tolerate enteral nutrition in either the short term
as a result of postoperative gastrointestinal dysfunction or
in the long termas a result of loss of intestinal length (1, 2).
TPN, however, leads to mucosal atrophy due to decreased
intestinal epithelial cell (IEC) proliferation and increased
apoptosis, with resultant loss in mucosal epithelial barrier
function (EBF), decline in the size of the crypt/villus
complex, and reduction in intestinal length (3–5). Using
a mouse TPN model, we previously showed that mucosal-
derivedepidermal growth factor (EGF) and its downstream
signals are down-regulated while TNF-a is up-regulated.
Importantly, both changes contribute to an overall phe-
notype of mucosal atrophy (6).
An important signaling pathway which drives TNF-a ex-
pression is via TLR activation. In particular, activation of
TLR4 via signaling through a MyD88/TRIF downstream
signaling pathway can signiﬁcantly up-regulate a number of
proinﬂammatory cytokines, including TNF-a. Interestingly,
TLR4 signaling ismarkedly up-regulated in our TPNmodel
in a MyD88-dependent fashion (6). In fact, our laboratory
has shown that knocking out the TLR common adaptor
MyD88 led to a prevention of TNF-a expression (7).
The interdependence of TLR signaling on IEC survival
has been demonstrated previously. Sodhi et al. showed that
when TLR4 is deleted in the IEC population, intestinal
proinﬂammatory processes, such as a mouse necrotizing
enterocolitis model, were prevented with resultant mini-
mal cytokine elevation and preservation of small intestine
mucosa (8).
It is well appreciated that ErbB1 is critical for mediating
IEC proliferation and antiapoptotic actions (9, 10). In-
terestingly, a link between successful EGF/ErbB1 signaling
and integrity of TNF-a signaling has been shown. Kaiser
and Polk showed that TNF-a receptor (TNFR) 1 signaling
inhibited proliferation, whereas TNF-a R2 (TNFR2) pro-
moted proliferation (11). The same laboratory later
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showed that activation of TNFR1 signaling inhibited EGF
stimulated proliferation by promoting internalization of
EGFR (12). This interdependence of TNF-a signaling and
EGFmay have strong relevance to TPN-associated atrophy.
Our laboratory has shown that EGF failed to drive effec-
tive IEC proliferation in an environment with increased
TNFR1 expression and an absence of TNFR2 (6). Thus,
EGF and TNFR1 appear to have distinct alternative roles in
modulating IEC proliferation and apoptosis; however, it is
not clear what factors may be driving the strong TNFR1
signaling with TPN administration.
A critical link between EGF and TLR signaling has also
been observed to modulate IEC proliferation and apo-
ptosis (10). Hsu et al. found that in the colon TLR4
activation up-regulated the EGF receptor ligands amphir-
egulin and epiregulin (13). The mechanisms driving such
activation between TLR4 and EGF-signaling pathways has
been reported. Fukata and Abreu described that TLR4
activation induces cyclooxygenase 2 and prostaglandin E2
production, which can then activate the EGF receptor
(EGFR) pathway (14). However, despite these observa-
tions, the exact mechanisms and interrelations of these 2
important signaling pathways are not clear.
Because our TPN mouse model shows signiﬁcant in-
testinal atrophy due to a loss of EGF and the presence of
increased TLR abundance, this TPNmodel offers a useful
approach to investigate the interaction of these pathways
(6, 7). We hypothesized that EGF signaling is preserved in
TLR4 knockout (TLR4KO)-TPN mice and may function
to prevent mucosal atrophy.
The current work demonstrates for the ﬁrst time that
small intestinal architecture and barrier function are sig-
niﬁcantly altered without effective TLR4 signaling. It also
demonstrates the novel ﬁnding that TPN-associated in-
testinal mucosal atrophy is prevented in TLR4KO mice as
a result of sustained epithelial proliferation and reduced
apoptosis.LossofTLR4signaling in thismodel also resulted
in apreservationofEGFexpressionanddecreasedmucosal
abundance of TNF-a. The present work demonstrates the
critical role TLR4 has on modulation of intestinal growth
and suggests that strategies to modulate TLR4 signaling
may be beneﬁcial in patients receiving TPN.
MATERIALS AND METHODS
Animals
C57Bl/6male, speciﬁc-pathogen-free9- to10-week-oldmalemice
(The Jackson Laboratory, Bar Harbor, ME, USA) were main-
tained under temperature-, humidity-, and light-controlled con-
ditions. Bodyweight and age-matchedmaleTLR4-knockoutmice
(TLR4KO; 007227, B6.B10ScN-Tlr4lps-del/JthJ; Jackson Labora-
tory) were also studied. The mice were initially fed standard
mouse chow and water ad libitum and were allowed to acclimate
for 1 week before surgery. During the administration of in-
travenous solutions, the mice were individually housed in meta-
bolic cages to prevent coprophagia. The study protocol was
approved by University of Michigan Committee on the Use and
Care of Animals (approval #3986).
Operative procedures and TPN delivery
Cannulation and administration of TPN was identical with that
previously described (15, 16). TPN mice received intravenous
TPN at 4.8ml per day. Nitrogen andenergy delivery wasmatched
between groups (isonitrogenous/isocaloric). This TPN solution
and the administration rate allow for adequate caloric delivery,
matching the amount that the enterally fed mice received (16,
17). The sham treatment group consisted of enterally fed mice
provided intravenous saline at the same rate (4.8 ml per day) as
the infusions in the TPN group. Mice were euthanized with car-
bon dioxide 7 days after cannulation. Body weight was recorded
on the day of cannulation and just before euthanasia. Mice were
killed early if their health deteriorated to a level found to be
unacceptable for their well-being and were not included in the
ﬁnal data analysis.
EGF blockade
For the pharmacologic EGFblockade, animals were provided the
ErbB1 inhibitor geﬁtinib (LC Laboratories, Woburn, MA, USA;
2.5 mg/ml in 1% aqueous Tween-80, 200 ml per dose) by oral
gavage twice daily starting 3 days before cannulation and con-
tinued until animals were killed. As with other groups, mice were
killed early if their health deteriorated to a level found to be
unacceptable for their well-being and were not included in the
ﬁnal data analysis.
Intestinal morphology assessment
Villus length and crypt depth were measured in $10 well-
oriented, full-length crypt–villus units per specimen and aver-
aged. Data were analyzed with commercially available digital
image analysis software (NIS-Elements, AR 3.0; Nikon, Melville,
NY, USA).
RNA isolation and quantitative real-time PCR (RT-PCR)
RNA extraction from mucosal scrapings was performed accord-
ing to published procedures (18, 19). qPCR was measured with
a Rotor-Gene 6000 (Qiagen, Hilden, Germany), and b-actin or
18S R1 ribosomal RNA was used as the internal control for nor-
malization. Table 1 lists the primer sequences.
Western immunoblot analysis
The isolationof IECs andWesternblot analysiswereperformedas
previously described (20) with primary antibodies including the
following: mouse anti-Bax (1:200, sc-7480; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), mouse anti-Bcl-2 (1:200, sc-
7382; Santa Cruz Biotechnology), mouse anti-phospho-Ikba
(Ser32/36; 1:1000, 9246; Cell Signaling Technology, Danvers,
MA, USA), mouse anti-Ikba (L35A5 Amino terminal antigen;
1:1000, 4814; Cell Signaling Technology), mouse anti-phospho-
ERK(Thr202/Tyr204; 1:1000, 9106S;Cell SignalingTechnology),
rabbit anti-ERK1/2 (1:1000, 9102; Cell Signaling Technology),
rabbit anti–phosphorylated protein kinase B 1/2/3 (p-AKT;
Ser473 and Thr308; 1:200, sc-25658; Santa Cruz Biotechnology),
mouse anti–proliferating cell nuclear antigen (PCNA; 1:3000,
(continued from previous page)
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2586;Cell SignalingTechnology), andmouseanti-b-actin (1:1000,
sc-130300; Santa Cruz Biotechnology). The secondary antibody
usedwas the horseradish peroxidase conjugate of either goat anti-
mouse or goat anti-rabbit IgG (1:2000; Santa CruzBiotechnology)
as appropriate.
IF microscopy
Sections of jejunum (5 mm) were embedded in parafﬁn and
placed on slides by our pathology department. Immunoﬂuores-
cence (IF) staining was performed (18) with primary antibodies
including the following: mouse anti-PCNA (1:3000, 2586, Cell
Signaling Technology), mouse anti-5-bromo-2-deoxyuridine
(BrdU; 1:50, sc-56255; Santa Cruz Biotechnology), rabbit anti-
occludin (6:1000, ab31721; Abcam, Cambridge, MA, USA),
mouse anti–claudin 2 (5:1000, 325600; Invitrogen, Carlsbad, CA,
USA), and rabbit anti–zonula occludens-1 (ZO-1; 1:100, 617300;
Invitrogen). Secondary antibodieswereAlexaFluor 488goat anti-
mouse IgG (1:500, A21121; Invitrogen) or Alexa Fluor 555 don-
key anti-rabbit IgG (1:1000, A31572; Invitrogen) as appropriate.
DAPI stainingwas performedwith ProlongGold antifade reagent
with DAPI (P36935; Life Technologies, Carlsbad, CA, USA).
IEC proliferation assessment
IECproliferationwas assessed by IF stainingof themarkers PCNA
and BrdU as previously described (21).
IEC apoptosis assessment
IEC apoptosis was assessed by TUNEL and caspase 3 staining as
previously described (21).
Ussing chamber and permeability studies
Experiments were performed in modiﬁed Ussing chambers
(Physiologic Instruments, San Diego, CA, USA) on jejunal seg-
ments as previously described (22). Transepithelial resistancewas
determined according toOhm’s law. Permeability of the jejunum
was assessed by measuring mucosal-to-serosal permeation of
FITC-dextran (FD4; average molecular weight, 3000–5000;
Sigma-Aldrich, St. Louis, MO, USA) as previously described (23).
Brieﬂy, 150ml FITC-dextran (50mg/ml, diluted with fresh Krebs
buffer) was added to themucosal compartment after a 30-minute
equilibration period. Then 500 ml samples were removed from
the serosal compartment every 30minutes, and ﬂuorescence was
measuredwithaSynergy2multimodemicroplate reader (BioTek
Instruments, Winooski, VT, USA) at an excitation wavelength of
492 nm and an emission wavelength of 515 nm. Permeability was
expressed as the percentage of mucosal-to-serosal clearance of
FITC-dextran.
Statistical analysis
Data are expressed as means 6 SD. All experiments were per-
formed with .6 mice per group. A preliminary power analysis
determined that a minimum of 6 subjects per study group would
be needed on the basis of previous variance data from pro-
liferation assays, our primary outcome measure. Student’s t tests
were used for comparing 2 groups. ANOVA with Tukey post hoc
testing was used to compare multiple groups. Signiﬁcance was
deﬁned as P, 0.05.
RESULTS
TLR4KO mice provided TPN show less intestinal
atrophy compared to WT-TPN mice
Enterally fed TLR4KO-sham mice had similar gross small
bowel characteristics compared to wild-type (WT)-sham
mice (Fig. 1A). In contrast, loss of TLR4 signaling led to
profound changes with TPN administration. WT mice
undergo a signiﬁcant decrease in small intestinal length
withTPNadministration (P, 0.0001); however, TLR4KO-
TPN mice showed no signiﬁcant loss in length (Fig. 1A).
When evaluated as a percentage change in small intestinal
length (compared to the sham intestinal length of each
group), the TLR4KO-TPNmice had a 4-fold lower decline
TABLE 1. RT-PCR primer sequences
Mouse gene Forward (59–39) Reverse (59–39)
Bcl-2 ATGCCTTTGTGGAACTATATGGC GGTATGCACCCAGAGTGATGC
Bax TGAAGACAGGGGCCTTTTTG AATTCGCCGGAGACACTCG
Fas GGTGGAAACAAACTGCACCC ACAGTGTTCACAGCCAGGAG
FasL ACCGCTCTGATCTCTGGAGT GGCTGGTTGTTGCAAGACTG
TNF-a CCGGGAGAAGAGGGATAGCTTGG TCGGACAGTCACTCACCAAGT
IFN-g ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCTC
TLR-2 ACAATAGAGGGAGACGCCTT AGTGTCTGGTAAGGATTTCCCAT
TLR-5 CTGCAACTGTGAACTTAGCA ACTTTAGGGACCGCAT
TLR-7 TGTCTCTTCCGTGTCCACAT GGATGATCCTGGCCTATCTC
TLR-9 CTGTACCAGGAGGGACAAGG CAGTTTGTCAGAGGGAGCCT
IL-6 TCTCTGGGAAATCGTGGAAA GATGGTCTTGGTCCTTAGCC
IL-10 ACCTGGTAGAAGTGATGCCCCCAGGCA CTATGCAGTTGATGAAGATGTCAAA
EGF TTCTCACAAGGAAAGAGCATCTC GTCCTGTCCCGTTAAGGAAAAC
EGFR GCATCATGGGAGAGAACAACA TCAGGAACCATTACTCCATAGGT
Amphiregulin GGTCTTAGGCTCAGGCCATTA CGCTTATGGTGGAAACCTCTC
HB-EGF CGGGGAGTGCAGATACCTG TTCTCCACTGGTAGAGTCAGC
Epiregulin CTGCCTCTTGGGTCTTGACG GCGGTACAGTTATCCTCGGATTC
b-Actin ATGGAGCCGGACAGAAAAGC CTTGCCACTCAGGGAAGGA
18S ribosomal
RNA
ATCGACACTTCGAACGCACT CACACGTCTGAACTTCGGGA
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Figure 1. Gross and microscopic morphometric measurements of TLR4KO andWTmice. A) Mean small intestine lengths. B) Percentage
change in small intestine length with TPN administration in WT and TLR4KO groups. C) Differences in crypt depth. D) Differences in
villus length. Results represent means 6 SD, n = 6/group. *P , 0.05. E) Differences in transepithelial resistance for each study group.
F) Permeability of FITC-dextran for each study group. G) Representative images of ZO-1 and occludin staining for each group.
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comparedtoWT-TPNmice(25.4166.9%vs.222.4063.3%,
respectively; P , 0.0001; Fig. 1B).
Although grossly TLR4KO mice did not appear differ-
ent, when compared microscopically, TLR4KO mice had
signiﬁcantly deeper crypts thanWTmice in both the sham-
treated (1.3-fold deeper; P = 0.002; Fig. 1C) and TPN
groups (1.4-fold deeper; P = 0.0004; Fig. 1C). Additionally,
while TLR4KOmice undergo loss of crypt depth with TPN
administration, crypts remain deeper than their WT-TPN
counterparts. With respect to villus length (Fig. 1D),
TLR4KO-sham mice were similar to WT-sham mice. With
TPN administration, TLR4KO mice showed loss of villus
length; however, the resultant decline in length was not
signiﬁcantly different from WT-TPN mice. Overall, there
was a protection of both intestinal length and crypt depth
in a proinﬂammatory model with TLR4KO.
Enterally fed TLR4KO mice have stronger EBF
Another consequence of TPN-associated mucosal atrophy
is a loss of EBF (24). To address the effect of removing
TLR4 signaling in the TPN model, we examined 2 meas-
ures of barrier function. For enterally fed groups, it was
interesting to note that TLR4KO-sham mice had higher
transepithelial resistance compared to WT-sham mice
(40.3 6 3.1 vs. 27.7 6 5.2 V×cm2; P = 0.003; Fig. 1E).
However, this increase in EBF was lost with TPN adminis-
tration. With TPN, both WT and TLR4KO groups had
a similar decline in transepithelial resistance (11.386 1.8
vs. 12.76 1.8V×cm2; P = 0.32; Fig. 1E).
EBF was also measured by permeation of a tracer mol-
ecule (FITC-dextran). Permeation was decreased in en-
terally fed TLR4KO mice, suggesting improved EBF at
baseline. Interestingly, the typical 6-fold increase in FITC-
dextran permeation observed in WT-TPN mice was not
observed in the TLR4KO-TPN group (Fig. 1F). In fact,
there was minimal change in permeation between
TLR4KO-sham and TLR4KO-TPN groups.
To further examine the structural changes in tight
junction integrity, we analyzed IF staining of several junc-
tional proteins, including ZO-1, occludin, and claudin 2.
Our laboratoryhaspreviously showna signiﬁcantdecline in
both ZO-1 and occludin in WT mice with TPN adminis-
tration (24). When looking at the TLR4KO mice, there
wereno signiﬁcant changes inZO-1 (Fig. 1G) and claudin 2
(data not shown) staining between TLR4KO-sham and
TLR4KO-TPN groups. Occludin did appear to be slightly
decreased in theTLR4KO-TPNgroup.However, the typical
internalization of occludin protein with TPN administra-
tion in WT mice was not observed in the TLR4KO group
(Fig. 1G).
TLR4KO mice have increased IEC proliferation
The differences observed in the crypt morphology could
represent either an expansion in IEC proliferation or a loss
of IEC apoptosis. Therefore, we next examined IEC pro-
liferation rates using BrdU and PCNA staining. WT mice
had a signiﬁcant loss of IEC proliferation with TPN ad-
ministration as measured by signiﬁcant declines in both
BrdU and PCNA staining (218.7% and 228.4%,
respectively; Fig. 2). Interestingly, this marked decline in
IEC proliferation was nearly completely prevented in
TLR4KO-TPN mice, and levels of proliferation were not
signiﬁcantly different compared to TLR4KO-shammice.
Thus, maintenance of IEC proliferation in TLR4KO
mice was a contributing mechanism preventing TPN-
associated atrophy.
TLR4KO have decreased crypt IEC apoptosis rates
We then examined IEC apoptosis rates using TUNEL
staining (Fig. 3A, B). With TPN administration, villi apo-
ptosis rates increased 5-fold inWTmice and almost 10-fold
in TLR4KO mice. In WT mice, crypt apoptosis rates in-
creased 1.8-fold with TPN and was similar to levels pre-
viously described by our group. However, TLR4KO mice
showed very low levels of apoptotic positive crypt cells in
both the sham-treated and TPN groups. As a result, apo-
ptotic positive crypt cells were 23-fold higher in WT-TPN
than in TLR4KO-TPNmice.
To complement TUNEL staining, caspase 3 staining was
also completed. Similar to our TUNEL staining, crypt apo-
ptosis rates were signiﬁcantly decreased in TLR4KO mice.
Interestingly, however, there was a signiﬁcant increase in
villous IECapoptosis rateswithTPNadministration for both
WT and TLR4KO groups (Fig. 3). This suggested that the
regulatory pathways that intersect between TLR4 and EGF
signaling may reside within the crypt region of the mucosa.
To account for this signiﬁcant reduction in crypt cell ap-
optosis, Bcl-2 (antiapoptotic) and Bax (proapoptotic) ex-
pression were then measured in mucosal scrapings at the
RNAlevel (Fig.4A–C).For sham-treatedmice,TLR4KOlevel
of Bcl-2 was 9-fold higher thanWTmice (P = 0.003); for TPN
mice, TLR4KOwas 1.6-fold higher thanWTmice (P = 0.004;
Fig. 4A). Overall, WTmice showed a 4-fold increase in Bcl-2
with TPN administration, while TLR4KO-TPNmice showed
a 1.3-fold decrease. For Bax (Fig. 4B), there was a 10-fold
decrease in TLR4KO-TPN compared to the 4-fold increase
observed with TPN administration in WT mice.
We next examined the Bax/Bcl-2 ratio (Fig. 4C), as this
ratio may have more physiologic relevance to overall de-
velopment of apoptosis (25). While sham-treated groups
were similar between WT and TLR4KO mice, WT mice
showed a 1.7-fold increase in the ratio with TPN administra-
tion; however, inTLR4KO-TPNgroup,weobserved a14-fold
decrease in theBax/Bcl-2 ratio.Asaresult, theTLR4KO-TPN
ratio was 24-fold lower than the WT-TPN ratio (P = 0.0009).
Thus, this alteredbalanceof pro- and antiapoptosis factors
may contribute to the mechanisms decreasing atrophy of
the small intestine with TPN administration.
Wehavepreviouslydescribedan increase in theextrinsic
apoptosis pathway in ourTPNmodel via a 2.5-fold increase
in FasL expression (19). In TLR4KO-shammice, there was
a 5.7-fold decrease in FasL compared to WT-sham mice
(0.000446 0.0003 vs. 0.00256 0.0005; P = 0.015; Fig. 4D).
Although both TLR4KO groups had lower concentrations
of Fas than their WT counterparts (Fig. 4E), these differ-
ences did not reach signiﬁcance, and FasL abundances
were not signiﬁcantly different in the TPN groups.
Another downstream pathway that could drive apoptosis
is the up-regulation of NF-kB with TPN administration in
WT mice (26). Previous research has shown that LPS
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activates NF-kB through TLR4-dependent and -indepen-
dent pathways in the colon (27). Interestingly, when com-
paring phosphorylated Ikba to nonphosphorylated Ikba,
there was no change in the ratio with TPN administration
in TLR4KO mice (Fig. 4F). However, when comparing
TLR4KO-TPN and WT-TPN ratios, there was a 1.75-fold
increase in this ratio, suggesting a decline in NF-kB activa-
tion in TLR4KO-TPN mice (P = 0.04), which is consistent
with previously published literature on TLR4KO mice in
a dextran sodium sulfate inﬂammatory model (28). In
summary, an overall decrease in apoptosis also contributes
to preservation of intestinal length and crypt depth.
TLR4KO have decreased TNF-a but increased
IFN-g abundance
Our laboratory has previously reported a signiﬁcant in-
crease in theexpressionofproinﬂammatory cytokineswith
the administrationofTPN; as wenoted above, this is driven
by an up-regulation of NF-kB activation (6, 29). Therefore,
to look at other possible contributing factors that led to the
preservation of proliferation and prevention in apoptosis,
we next analyzed changes inmucosal expression of several
cytokines. TNF-a increased with TPN administration in
WT mice (2-fold over sham-treated group; P = 0.008;
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Figure 3. Epithelial cell apoptosis results using TUNEL and caspase 3 staining. A) Mean TUNEL-positive IEC per 100 villi are
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Fig. 5A), similar towhatwepreviously reported(6).Despite
the decline in NF-kB activation in TLR4KO mice, they
showed very little change in TNF-a concentration with
TPN administration, and TNF-a levels were similar be-
tween TLR4KO-TPN and WT-sham mice.
WTmiceshowedan increase inbothTNFR1andTNFR2
with TPN administration (Fig. 5B, C), with only the in-
crease in TNFR2 being signiﬁcant (P = 0.008; Fig. 5C). In
both TLR4KO groups, we found that abundances of
TNFR1 and TNFR2 were both up-regulated to levels simi-
lar to those in WT-TPNmice (Fig. 5B, C).
Interestingly, a marked increase in IFN-g was noted in
TLR4KO mice with TPN administration that was not
observed in the WT-TPN mice (Fig. 5D). There were no
changes in IL-6 and IL-10 abundances (Fig. 5E, F).
This suggested that the loss ofTLR4 signalingmay lead to
an up-regulation in other proinﬂammatory cytokines, po-
tentially via signaling through alternative TLRs. To address
this, we then examined expression of other TLRs by RT-
PCR. This showed a 10-fold increase in TLR2 (P = 0.05; Fig.
5Gi) and a 17-fold increase in TLR5 (P = 0.03; Fig. 5Gii)
between enterally fed TLR4KO versus WT mice. The in-
crease in TLR2 decreased 3-fold with TPN administration
(P = 0.0003; Fig. 5Gi); however, the TLR5 abundance in
TLR4KO-TPNmice decreased to levels similar to WT-TPN
mice. No differences in TLR7 abundances were detected
Figure 4. Epithelial cell apoptosis results and contributing apoptotic pathways. A–C) Factors are measured by RT-PCR of jejunal
mucosal scrapings, corrected to expression of 18S. They represent Bcl-2, Bax, and the Bax/Bcl-2 ratio, respectively. D, E) Fas
ligand and Fas mRNA expression adjusted as a ratio to b-actin expression. F) Representative Western blot of phosphorylated Ikba
to Ikba and ratio of these factors. Results represent means 6 SD, n = 6/group. *P , 0.05.
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Figure 5. mRNA cytokine expression using RT-PCR of selected cytokines and receptors and TLRs. A) Changes in TNF-a. B, C)
Changes in TNFR1 and TNFR2, respectively. D) changes in IFN-g. E, F) Changes in IL-6 and IL-10, respectively. Gi–iv) show
changes in selected TLRs as a result of the knockout of TLR4 by RT-PCR. mRNA expression is corrected to the expression of 18S.
Results represent means 6 SD, n = 6/group. *P , 0.05.
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betweenTLR4KOandWTmice(Fig. 5Giii).With respect to
TLR9, WT mice had an increase in abundance with TPN
administration. For the TLR4KOmice, TPN resulted in no
signiﬁcant change in TLR9 abundance. As a result, there
was a signiﬁcant 6-fold decrease between WT-TPN and
TLR4KO-TPN (P = 0.02; Fig. 5Giv).
TLR4KO mice show increased mucosal expression
of EGF
Our laboratory has previously shown a tight interrelation
between increases inTNF-a signalingwithTPNandadecline
in the mucosal expression of EGF (6). We next examined
mechanisms that contributed to preserved IEC proliferation
in our TLR4KO-TPN mice, as well as whether this preserva-
tion of IEC proliferation was due to an interdependency of
TLR4 and EGF. Interestingly, mucosal EGF mRNA was sig-
niﬁcantly increased (26-fold) in TLR4KO-sham versus WT-
shammice(0.03260.003vs.0.001260.0003;P=0.0006;Fig.
6A). Although levels declined with TPN in TLR4KO-TPN
mice,EGFremained6-foldhigher inTLR4KO-TPN vs.WT-
TPNmice (0.02060.005 vs.0.003360.002;P=0.0001; Fig.
6A). Our laboratory has shown that loss of ErbB1 is amajor
signaling mechanism that leads to mucosal atrophy in our
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Figure 6. EGF/EGFR and downstream signaling factors. A, B) Changes in EGF and EGFR, respectively, by RT-PCR of jejunal
mucosal scrapings. C) Changes in amphiregulin by RT-PCR. D, E) Representative blots from analysis of Western immunoblots of
epithelial cell lysate. D) Ratio of p-AKT to b-actin. E) Ratio of phosphorylated Erk to Erk. Results represent means 6 SD,
n = minimum of 5/group. *P , 0.05.
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TPN model (6). The expression of the EGF receptor,
ErbB1, however, was not signiﬁcantly changed between
TLR4KO and WTmice (Fig. 6B).
In addition, previous studies have suggested that the
ErbB1 ligand amphiregulin is critical for mediating pro-
liferation in a TLR4-dependent pathway (13). Therefore,
we examined amphiregulin abundance, but we did not
detect any signiﬁcant changes between groups (Fig. 6C).
Other ErbB ligands analyzed (heparin-binding epidermal
growth factor [HB-EGF], epiregulin, and neuroregulin
[NRG] 1, NRG3, and NRG4) also failed to show any sig-
niﬁcant changes between study groups.
We next examined several dominant downstream sig-
naling pathways for EGF using immunoblotting. We have
previously identiﬁed a loss of p-AKT expression with TPN
administration (6, 21). In addition, previous work had
shown that exogenous EGF partially prevented the loss of
p-AKT signaling inTPNmice (6). For TLR4KO-TPNmice,
there was a 4.4-fold increase in p-AKT compared to WT-
TPN mice (Fig. 6D). A downstream pathway that is up-
regulated with TPN administration and may contribute to
loss of IEC function is the phosphorylation of ERK (6). In
TLR4KO-TPN mice, there was a relative decrease in the
phosphorylated Erk/ERK ratio compared to WT-TPN
mice (Fig. 6E). Thus, it appears thatTLR4KOmicehave an
up-regulation of EGF abundance and EGF downstream
signaling pathways.
EGF blockade prevents rescue from TPN-associated
atrophy in TLR4KO mice
To verify our hypothesis that EGF signaling is augmented
in the absence of an intact TLR4 receptor, we blocked
the ErbB1 receptor using geﬁtinib in TLR4KO-sham and
TLR4KO-TPN mice. Our laboratory has previously
shown that ErbB1 blockade in WT-TPN mice results in
a signiﬁcant decline in mucosal-derived EGF and ErbB1.
We also showed an increasedmortality from 0 to 30%with
EGFblockade (6). In thepresent study, geﬁtinib treatment
of TLR4KO-TPN mice resulted in increased mortality
(from 0 to 25%). Geﬁnitib treated animals appeared
hunched and scruffy at time of killing, suggesting a much
poorer clinical condition. All TPN groups lost weight with
TPN; however, TLR4KO-sham with geﬁtinib was the only
enterally fed group to lose weight. (Fig. 7A).
ErbB1 blockade resulted in a loss of intestinal length in
most groups (Fig. 7B).The reduction in intestinal length in
WT-TPN mice was not signiﬁcantly different from that of
TLR4KO-TPN mice. When we calculated the percentage
loss of intestinal length, it was similar between WT mice
provided TPN and both TLR4KO groups provided EGF
blockade (Fig. 7C). This suggests that enhanced EGF sig-
naling was responsible for the preservation of intestinal
length in TLR4KO-TPNmice.
The increase in crypt depth observed in TLR4KO-sham
groupwaslostwithEGFblockade(115.364.95vs.70.7364.49;
P, 0.0001; Fig. 7D). In fact, TLR4KO-sham mice treated
with EGF blockade had crypts of similar depth toWT-TPN
mice. Additionally, TLR4KO-TPN mice treated with geﬁ-
tinib had the shallowest crypts of all groups. There was
a 2.3-fold decrease in crypt depth compared to TLR4KO-
TPN and a 1.6-fold decrease compared to WT-TPN mice.
EGF blockade resulted in signiﬁcant decrease in villus
height in bothTLR4KO-sham(458.1649.1 vs. 164.968.8;
nontreated vs. treated; P , 0.0001; Fig. 7E) and
TLR4KO-TPN groups (291.1 6 89.8 vs. 97.6 6 11.7;
P , 0.0001; Fig. 7E). Interestingly, villus height in
TLR4KO-sham mice provided EGF blockade group
(2.3-fold) and TLR4KO-TPN with EGF blockade group
(3.9-fold) were both signiﬁcantly shorter thanWT-TPN
mice (P , 0.0001 for both; Fig. 7E).
When staining for junctional proteins, ZO-1 appeared to
be minimally affected by the ErbB1 blockade; however,
occludin was severely affected, with a major decrease in
expression.TheErbB1blockadeTLR4KO-TPNgrouphad
disorganized, intracellular staining for occludin (Fig. 7F).
Proliferation as measured by PCNA staining was signiﬁ-
cantly decreased in both the TLR4KO-sham (P = 0.007)
and TLR4KO-TPN (P , 0.0001) groups that received
ErbB1 blockade compared to their TLR4KO counterparts
that did not receive the blockade (Fig. 7G). In fact, the
proliferation rates in both groups were similar to rates
observed in WT-TPN mice.
TLR4KO-TPN mice treated with ErbB1 blockade
showed a 15-fold increase in apoptotic positive crypt cells
compared toTLR4KO-TPNmice(Fig. 7H).This resulted in
anaverageapoptosis rate similar toWT-TPNmice(23.0+11.5
vs. 29.4+15.9; P = 0.63). When examining causes of this
increase inapoptosis, a43-folddecrease in theexpressionof
Bcl-2 was found inTLR4KO-shamgeﬁtinibmice compared
to TLR4KO-sham group (P , 0.0001; Fig. 8A), which was
a similar level as we found in theWT-shamgroup (P = 0.43).
The TLR4KO-TPN mice treated with EGF blockade also
had a 16.8-fold decrease in Bcl-2 mRNA compared to
TLR4KO-TPN mice (P , 0.0001; Fig. 8A) and a 9.3-fold
decrease compared to the WT-TPN group (P = 0.01; Fig.
8A). When we analyzed Bax abundance, there was a signif-
icant increase in the TLR4KO-sham with EGF blockade
comparedtoboththeWT-sham(0.2560.05vs.0.04260.02;
P = 0.01; Fig. 8B) and TLR4KO-sham (0.25 6 0.05 vs.
0.03560.008;P=0.01; Fig. 8B) groups.TheTLR4KO-TPN
with EGF blockadewas similar to the TLR4KO-TPNgroup
and 5.3-fold lower than the WT-TPN group (Fig. 8B).
WhenweanalyzedFasandFasLwithErbB1blockade,we
found a signiﬁcant increase in FasL in both the TLR4KO-
sham (P = 0.02) and TLR4KO-TPN (P = 0.03; Fig. 8C)
groups. Interestingly, we saw a 4.6-fold increase in Fas
abundance in the TLR4KO-TPN mice that received geﬁ-
tinib compared to the untreated TLR4KO-TPN mice
(0.0316 0.008 vs. 0.00686 0.001; P = 0.02; Fig. 8D).
The TLR4KO-sham with EGF blockade group experi-
enced a signiﬁcant increase inTNF-a compared tobothWT-
sham (5.3-fold; P , 0.0001) and TLR4KO-sham (4.3-fold;
P = 0.0006) groups (Fig. 8E). Interestingly, TLR4KO-TPN
mice treated with geﬁtinib had similar TNF-amucosal levels
compared to both WT-TPN and TLR4KO-TPN (P = 0.16)
groups. Because we previously found an increase in IFN-g in
theTLR4KO-TPNgroup,wewanted to examine theeffect of
bothEGFblockadeandTPNonIFN-g concentrations.There
was no signiﬁcant difference between the 3 sham-treated
groups. In the TLR4KO-TPN with EGF blockade group, we
saw an additional 2.0-fold increase in IFN-g concentration
compared to the TLR4KO-TPN group (0.00716 0.001 vs.
0.00366 0.001; P = 0.0002; Fig. 8F), for a total of a 4.0-fold
increase over the WT-TPN group (P, 0.0001; Fig. 8F).
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Because we identiﬁed an increase in abundance of
TLR2 with TLR4KO, we also examined the abundance of
TLR2 in TLR4KO groups that received ErbB1 blockade.
There was no change in TLR2 abundance between
TLR4KO-sham and TLR4KO-sham with EGF blockade.
However, when comparing TLR4KO-TPN and TLR4KO-
TPN with EGF blockade, there was a 7.2-fold decrease in
TLR2 abundance to an amount similar to WT-TPN mice
(0.0246 0.009 vs. 0.00346 0.002; P = 0.008; Fig. 8G).
The TLR4KO-sham mice with EGF blockade no longer
had an up-regulation of EGF, as seen with the TLR4KO-
sham counterparts. Their EGF levels were more similar
to WT mice (Fig. 8H). TLR4KO-TPN with EGF block-
ade group had EGF levels similar to both the WT-TPN
(P = 0.26) and TLR4KO-TPN (P = 0.054) groups (Fig. 8H).
In summary, EGF signaling appears to be a domi-
nant mechanism that explains the beneﬁcial effects
in IEC physiology in TLR4KO-TPN mice. The data
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Figure 7. Effect of ErbB1 blockade on the small intestine of TLR4KO mice. A) Percentage change between preoperative and
postoperative weights for each group. B) Changes in small intestine lengths. C) Percentage change in small intestine length with
TPN and ErbB1 blockade. WT is the percentage change in small intestine length between WT-sham and WT-TPN mice. TLR4KO
is the percentage change in small intestine length between TLR4KO-sham and TLR4KO-TPN mice. TLR4KO-sham with EGF
blockade is the percentage change in small intestine length between TLR4KO-sham and TLR4KO-sham EGF blockade mice.
TLR4KO-TPN with EGF blockade is the percentage change in small intestine length between TLR4KO-sham and TLR4KO-TPN
EGF blockade mice. D) Differences in crypt depth for each study group. E) Differences in villus length for each study group. F)
Representative images of ZO-1 and occludin staining in ErbB1 blockade for TLR4KO sham and TLR4KO TPN groups compared
to WT groups. G) Changes in proliferation by changes in PCNA staining (%PCNA+ crypt cells). H, I) Changes in apoptosis by
TUNEL staining. Results represent means 6 SD, n = 6/group. *P , 0.05.
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also show a strong interdependence between TLR4
signaling and EGF/ErbB1.
DISCUSSION
This present work demonstrates a strong interdependence
of TLR4 and EGF signaling in the remodeling of the
crypt/villus architectureduringa stateof intestinal atrophy
driven by enteral nutrient deprivation. Several strikingly
novelﬁndingswereobserved in thepresent study.Ourdata
show that loss of intact TLR4 signaling within the intestine
led to a signiﬁcant decrease in mucosally derived TNF-a
abundance, with a resultant prevention in the loss of EBF
and IEC apoptosis. In addition, there was a signiﬁcant up-
regulation of EGF expression within the small intestinal
mucosa with a resultant increase in IEC proliferation.
Although previous publications have shown decreased
inﬂammation in other proinﬂammatory models when us-
ing the TLR4KO mice (8), TLR4 signaling in the present
work led to the novel ﬁnding of enhanced IEC growth and
prevention of atrophy via enhanced EGF expression. De-
creased apoptotic rates in TLR4KO-sham vs. WT-sham
were accompanied by unchanged Bax/Bcl-2 ratio and de-
creased Fas levels. This is consistent with extrinsic pathway
of apoptosis. On the other hand, increased apoptotic rates
inWT-TPN versus.WT-sham animals were accompanied by
increased Bax/Bcl-2 ratio and unchanged Fas levels. This is
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Figure 8. Changes in factors mediating apoptosis and selected cytokines and TLR after ErbB1 blockade in TLR4KO mice; results
measured by RT-PCR of jejunal mucosal scrapings. A, B) Changes in Bcl-2 and Bax, respectively. C, D) Changes in FasL and Fas,
respectively, with ErbB1 blockade. E, F) Changes in TNF-a and IFN-g, respectively. G) Changes in TLR2. H) Changes in EGF.
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consistent with the intrinsic rather than extrinsic pathway
being responsible for elevated apoptosis in TPN mice.
Theobserveddecreases inERKactivity also lead toother
deductions. TNFR-associated factor 6 (TRAF6) acts as
a signal transduction mediator between TLR4 and MAPK
pathways (30). TRAF6 can act both dependently and in-
dependently of TLR4.Althoughnot speciﬁcallymeasured,
TRAF6-dependent and -independent activity would likely
have decreased due to the knockout of TLR4, overall ob-
served decline in NF-kB activation, and observed decrease
in ERK phosphorylation. As a result, it is presumed that
MAPK activity would also be decreased.
It was interesting that our ﬁndings are different from
those of Hsu et al., who found a strong dependence on
TLR4 signaling and the ErbB1 ligands epiregulin and
amphiregulin (13). Using a dextran sodium sulfate colitis
model, theexpressionofbothof these ligandswereactually
decreased in TLR4KO mice, and TLR4 drove amphir-
egulin and epiregulin expression. In another work from
this same laboratory, Sodhi et al. showed that TLR4 sig-
naling promoted IEC proliferation via activation of the
same2ErbB1 ligands (8). Severaldifferencesexist between
our current study and the one by Hsu et al. First, we ex-
amined small bowel IEC,while their study involved colonic
epithelium. Additionally, we noted an increase in mucosal
expression of EGF in TLR4KO-TPN mice, which was not
reported by Hsu et al. Similar to Hsu et al., we did not see
a change in expression of amphiregulin in our TLR4KO-
TPN mice. Finally, our model of intestinal atrophy was
distinctly different than the inﬂammatory bowel disease
model used by this other group of investigators.
We believe that loss of TLR4 signaling in the fed group
did not signiﬁcantly change small bowel characteristics
because the majority of the bacterial population is made
upoforganisms likeBacteroides,whichdonot signal through
TLR4. Fed mice have a small percentage of Gram-
negative/LPS-positive bacteria.
Our work also showed that removal of TLR4 partially
prevented the loss of EBF in our TPNmodel. The removal
of TLR4 was shown to have a similar protective effect in
a neonatal mouse model of necrotizing enterocolitis (31).
Themechanisms that drive this protection in this previous
study were due to a prevention of enterocyte apoptosis and
prevention of mucosal injury. These were similar to the
morphologicﬁndings in the current work. In addition, our
work suggests that the partial preservation of EBFmay well
be due to a decline in TNF-a, but very possibly also due to
enhanced EGF abundance (24). In another study of nec-
rotizing enterocolitis, supplemental growth factors (in this
case, heparin-binding EGF) led to a strong preservation of
barrier function (32). Such action may be due to the
growth factor promoting IEC proliferation and its anti-
apoptotic actions (9).
It was interesting that TLR4KO mice demonstrated
several counterregulatory changes in ourTPNmodel. This
includeda rise inotherTLRsaswell as an increase in IFN-g.
Thus, while blockade of TLR4 had profound protective
actions with TPN-associated atrophy, careful examination
of the consequences of this blockade is needed. A limita-
tion of the present study was the use of a pan-TLR4KO
mouse model. Thus, it is unknown whether blockade of
TLR4 on IEC or other intestinal populations (e.g., immu-
nocytes) may be responsible for the ﬁndings reported
here. While we did not examine the microbiome pop-
ulations in this current study, we have reported such
changes with TPN administration (7). Although subtle
changes have been reported with loss of TLR4 signaling,
these changes are quite small compared to those seen in
our TPNmodel, and theymost likely did not contribute to
the altered mucosal growth observed in the current work
(33).
Further, the data suggest that an alteration in NF-kB
signaling with TLR4 blockade may play an important role.
It was interesting to note that phospho-Ikba was increased
in both TLR4KO groups. Recently, a better appreciation
thatNF-kBmay signal via type 1 and 2 pathways (canonical
andnoncanonical) (34),with adominantphosphorylation
of Ikba being via the NF-kB2 path. The prevention of IEC
apoptosis in TLR4KO mice suggests a modulation of the
NF-kB2 pathway (35); however, this will need to be ex-
plored further in future studies.
In conclusion, TLR4 blockade signiﬁcantly prevented
TPN-associatedatrophy,potentiallyvia reduction inTNF-a
abundance and elevation in EGF levels. Potential clinical
applications of such TLR4 blockademay prove potentially
useful in patients who are dependent on TPN and who are
susceptible to high rates of septicemia resulting from a loss
of EBF and who have a decreased ability to tolerate enteral
feedings due to intestinal atrophy.
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